Saharsh Davuluri Takes Over as CEO & MD of Neuland to Lead Next Phase of CDMO Expansion

Neuland Laboratories has announced a leadership change with Saharsh Davuluri assuming the role of Chief Executive Officer and Managing Director. The company has tripled its contract services revenues in the last 3 years and secured a growing number of commercial manufacturing contracts with global innovator companies. Saharsh has led Neuland’s transformation into a new chemical entity (NCE)-focused drug substance CDMO and will look to further accelerate this growth transformation over the next five years. Neuland is embarking on an aggressive expansion phase and could secure several more commercial NCE contracts over the next one to two years.